drugset / Trial / NCT01256268
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
Phase 1
Completed
24 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to: * Test the safety of a new investigational drug called MK-8669 (ridaforolimus) * Determine the maximum tolerated dose of MK-8669 * Determine the effectiveness of the maximum tolerated dose of MK-8669
Timeline
- Start
- 2011-06-13
- Primary completion
- 2016-02-03
- Completion
- 2017-08-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | 5 unknown | — |
| Subject | Carboplatin | Small molecule | 6 unknown | — |
| Subject | ridaforolimus | Small molecule | 10 mg | Oral |
| Subject | ridaforolimus | Small molecule | 20 mg | Oral |
| Subject | ridaforolimus | Small molecule | 30 mg | Oral |
| Subject | ridaforolimus | Small molecule | 40 mg | Oral |
| Background | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |